Previous 10 | Next 10 |
Lupkynis (voclosporin) received FDA approval in January 2021. Unwarranted sell-off after 1Q21 earnings release has created a buying opportunity. Anticipated solid Lupkynis revenue in 2Q21 and full year 2021. Doubling of share price achievable within 12 months. For furthe...
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (Aurinia or the Company) announced today the appointment of Dr. Brinda Balakrishnan, M.D., Ph.D., to the Company’s Board of Directors effective June 14, 2021. Dr. Balakrishnan is Group Vice President, Corporate and Busine...
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (“ Aurinia ” or the “ Company ”) is pleased to announce that the eight incumbent directors of the Company were elected at the Company’s annual general meeting (the “ Meeting ...
- New examination of AURORA 1 Phase 3 data demonstrates increased renal response rates with LUPKYNIS™ (voclosporin) used in combination with MMF and low-dose steroids in patients with lupus nephritis regardless of target urine protein creatinine ratio (UPCR) - - The...
AUPH recently released long-term data for its lupus nephritis drug LUPKYNIS. It also hosted an earnings call to go over the first two months of sales data. I use all of this new information to revise my sales estimates and stock target price. For further details see: Aur...
The price of Aurnia's shares is currently at an inflection point. I expect to see LupKynis sales figures skyrocket in the coming quarters. Aurinia currently presents an excellent investment opportunity, with huge upside potential, for the coming months/years. For further det...
An interim analysis of Aurinia Pharmaceuticals' (AUPH) LUPKYNIS (voclosporin) for lupus sustained meaningful reductions in proteinuria with no change in mean estimated glomerular filtration rate at 104 weeks of treatment.The analysis of 216 blinded subjects found that proteinuria co...
- Individuals treated with LUPKYNIS sustained meaningful reductions in proteinuria with no change in mean eGFR at 104 weeks of treatment - - These data, the longest-available outcomes data with LUPKYNIS for the treatment of lupus nephritis to-date, will be presented at Europea...
Biotech stocks are officially in a slump. After a rip-roaring 2020 fueled by the advent of COVID-19 vaccines and therapeutics, the iShares Nasdaq Biotechnology ETF has now lost 10% of its value in the past three months. The industry has suddenly lost favor with investors because of ...
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (the “Company”) today announced that members of the executive management team will participate in two upcoming investor conferences: RBC Capital Markets Global Healthcare Conference on Wednesday, May 19, 2021 at ...
News, Short Squeeze, Breakout and More Instantly...
Aurinia Pharmaceuticals Inc Company Name:
AUPH Stock Symbol:
NASDAQ Market:
Aurinia Pharmaceuticals Inc Website:
Viridien ADR (CGGYD) is expected to report for Q2 2024 Civitas Resources Inc. (CIVI) is expected to report $2.9 for Q2 2024 Aptiv PLC (APTV) is expected to report $1.37 for Q2 2024 Ardelyx Inc. (ARDX) is expected to report $-0.1 for Q2 2024 Beazer Homes USA Inc. (BZH) is expected ...
Company achieved $57.2 million in total net revenue and $55.0 million in net product revenue for the second quarter of 2024, representing year-over-year growth of approximately 38% and 34% respectively Company generated approximately $15.8 million in free cash flow in the second quarter a...
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that it will release financial and operational results for the second quarter of 2024 on Thursday, August 1, 2024, before markets open. Aurinia’s management team will host a conference call/webcast at 8:30...